Eli Lilly’s anti-obesity drug could surpass Ozempic

The American pharmaceutical company has revised its forecasts above and now expects annual sales between $45.4 and $46.6 billion, or $3 billion more than previously expected. This is the second time this year that the group has reviewed its forecasts. As the stock market opened, shares rose 14% before slowing to 7.5% during the day.

This drug that made Elon Musk lose 13 kilos, and made Coca-Cola fall on the stock market

Eli Lilly, like its competitor Novo Nordisk, is struggling to meet high demand for obesity drugs. So the American company added to the production of Zepbound, hoping to reduce the shortage. The company has also applied for a license to use its drug in the treatment of heart failure.